Activation of the phosphatidylinositide‐3‐kinase (PI3K)/serine/threonine‐specific protein kinase (AKT)/mammalian target of rapamycin (mTOR) pathway has been implicated in the growth and progression of various cancers, as well as resistance to standard anticancer therapies 2. Here, MTOR is linked to cancer.